Vaccines for Alzheimer's disease: How close are we?

CNS Drugs

Volumn 17, Issue 7, 2003, Pages 457-474

  Janus, Christopher ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY; AMYLOID PRECURSOR PROTEIN; CHELATING AGENT; CHOLESTEROL; CLIOQUINOL; DICLOFENAC; IBUPROFEN; M 266 ANTIBODY; METALLOPROTEIN; NCX 2216; NONSTEROID ANTIINFLAMMATORY AGENT; PROTEIN ANTIBODY; QS 21; UNCLASSIFIED DRUG;

ACTIVE IMMUNIZATION; ALZHEIMER DISEASE; CLINICAL TRIAL; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; MOUSE; NEUROPATHOLOGY; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; REVIEW; TRANSGENIC MOUSE; VALIDATION PROCESS; WORKING MEMORY;

ALZHEIMER DISEASE; ALZHEIMER VACCINES; AMYLOID BETA-PROTEIN; ANIMALS; DISEASE MODELS, ANIMAL; HISTORY, 21ST CENTURY; HUMANS; IMMUNOTHERAPY, ACTIVE; META-ANALYSIS; MICE; MICE, TRANSGENIC;

EID: 0037606205     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200317070-00001     Document Type: Review

References (113)

1. Evans DA, Funkenstein HH, Albert MS, et al. Prevalence of Alzheimer's disease in a community population of older persons: higher than previously reported. JAMA 1989; 262 (18): 2551-6
2. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34 (7): 939-44
3. Olshansky SJ. The human life span: are we reaching the outer limits? Geriatrics 1993; 48 (3): 85-8
4. Olshansky SJ, Carnes BA, Cassel CK. The aging of the human species. Sci Am 1993; 268 (4): 46-52
5. Alzheimer A. Über eine eigenartige Erkankung der Hirnrinde. Allg Z Psychiatrie Psychisch-Gerlichtlich Med 1907; 64: 146-8
6. Stelzmann RA, Schnitzlein HN, Murtagh FR. An English translation of Alzheimer's 1907 paper, "Uber eine eigenartige Erkankung der Hirnrinde". Clin Anat 1995; 8 (6): 429-31
7. Albert MS. Cognitive and neurobiologic markers of early Alzheimer's disease. Proc Natl Acad Sci U S A 1996; 93: 13547-51
8. Victoroff J, Zarow C, Mack WJ, et al. Physical aggression is associated with preservation of substantia nigra pars compacta in Alzheimer disease. Arch Neurol 1996; 53 (5): 428-34
9. Whitehouse PJ, Price DL, Struble RG, et al. Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science 1982; 215 (4537): 1237-9
10. Morrison JH, Hof PR. Life and death of neurons in the aging brain. Science 1997; 278 (5337): 412-9
11. Arnold SE, Hyman BT, Flory J, et al. The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer's disease. Cereb Cortex 1991; 1 (1): 103-16
12. Hyman BT, Van Hoesen GW, Damasio AR, et al. Alzheimer's disease: cell-specific pathology isolates the hippocampus formation. Science 1984; 225: 1168-70
13. Horn R, Ostertun B, Fric M, et al. Atrophy of hippocampus in patients with Alzheimer's disease and other diseases with memory impairment. Dementia 1996; 7: 182-6
14. Samuel W, Terry RD, Deteresa R, et al. Clinical correlates of cortical and nucleus basalis pathology in Alzheimer dementia. Arch Neurol 1994; 51 (8): 772-8
15. Jope RS, Song L, Powers RE. Cholinergic activation of phosphoinositide signaling is impaired in Alzheimer's disease brain. Neurobiol Aging 1997; 18 (1): 111-20
16. Tong XK, Hamel E. Regional cholinergic denervation of cortical microvessels and nitric oxide synthase-containing neurons in Alzheimer's disease. Neuroscience 1999; 92 (1): 163-75
17. Mattson MP, Pedersen WA. Effects of amyloid precursor protein derivatives and oxidative stress on basal forebrain cholinergic systems in Alzheimer's disease. Int J Dev Neurosci 1998; 16 (7-8): 737-53
18. Braak H, Braak E. Pathology of Alzheimer's disease. In: Calne DB, editor. Neurodegenerative diseases. Philadelphia (PA): Saunders, 1994: 585-613
19. Vigo-Pelfrey C, Lee D, Keim P, et al. Characterization of beta-amyloid peptide from human cerebrospinal fluid. J Neurochem 1993; 61 (5): 1965-8
20. Roher A, Wolfe D, Palutke M, et al. Purification, ultrastructure, and chemical analysis of Alzheimer disease amyloid plaque core protein. Proc Natl Acad Sci U S A 1986; 83 (8): 2662-6
21. Iwatsubo T, Odaka A, Suzuki N, et al. Visualization of A beta 42 (43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42 (43). Neuron 1994; 13 (1): 45-53
22. Feany MB, Dickson DW. Neurodegenerative disorders with extensive tau pathology: a comparative study and review. Ann Neurol 1996; 40 (2): 139-48
23. Grundke-Iqbal I, Iqbal K, Quinlan M, et al. Microtubule-associated protein tau: a component of Alzheimer paired helical filaments. J Biol Chem 1986; 261 (13): 6084-9
24. Grundke-Iqbal I, Iqbal K, Tung YC, et al. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci U S A 1986; 83 (13): 4913-7
25. Goate A, Chartier-Harlin MC, Mullan M, et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 1991; 349 (6311): 704-6
26. Chartier-Harlin MC, Crawford F, Hamandi K, et al. Screening for the beta-amyloid precursor protein mutation (APP717: Val - Ile) in extended pedigrees with early onset Alzheimer's disease. Neurosci Lett 1991; 129 (1): 134-5
27. Chartier-Harlin MC, Crawford F, Houlden H, et al. Early-onset Alzheimer's disease caused by mutations at codon 717 of the beta-amyloid precursor protein gene. Nature 1991; 353 (6347): 844-6
28. Sherrington R, Rogaev EI, Liang Y, et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 1995; 375 (6534): 754-60
29. Campion D, Flaman JM, Brice A, et al. Mutations of the presenilin I gene in families with early-onset Alzheimer's disease. Hum Mol Genet 1995; 4 (12): 2373-7
30. Levy-Lahad E, Wasco W, Poorkaj P, et al. Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science 1995; 269 (5226): 973-7
31. Rogaev EI, Sherrington R, Rogaeva EA, et al. Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. Nature 1995; 376 (6543): 775-8
32. Sherrington R, Froelich S, Sorbi S, et al. Alzheimer's disease associated with mutations in presenilin 2 is rare and variably penetrant. Hum Mol Genet 1996; 5 (7): 985-8
33. Lorenzo A, Yankner BA. Amyloid fibril toxicity in Alzheimer's disease and diabetes. Ann N Y Acad Sci 1996; 777: 89-95
34. Terry RD, Masliah E, Salmon DP, et al. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 1991; 30 (4): 572-80
35. Hyman BT, Marzloff K, Arriagada PV. The lack of accumulation of senile plaques or amyloid burden in Alzheimer's disease suggests a dynamic balance between amyloid deposition and resolution. J Neuropathol Exp Neurol 1993; 52 (6): 594-600
36. Berg L, McKeel DW, Miller JP, et al. Neuropathological indexes of Alzheimer's disease in demented and nondemented persons aged 80 years and older. Arch Neurol 1993; 50 (4): 349-58
37. Arriagada PV, Growdon JH, Hedley-Whyte ET, et al. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology 1992; 42 (3 Pt 1): 631-9
38. Spillantini MG, Murrell JR, Goedert M, et al. Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. Proc Natl Acad Sci U S A 1998; 95 (13): 7737-41
39. Greenberg BD, Savage MJ, Howland DS, et al. APP transgenesis: approaches toward the development of animal models for Alzheimer disease neuropathology. Neurobiol Aging 1996; 17 (2): 153-71
40. Hsiao K. Transgenic mice expressing Alzheimer amyloid precursor proteins. Exp Gerontol 1998; 33: 883-9
41. Seabrook GR, Rosahl TW. Transgenic animals relevant to Alzheimer's disease. Neuropharmacology 1999; 38 (1): 1-17
42. Price DL, Tanzi RE, Borchelt DR, et al. Alzheimer's disease: genetic studies and transgenic models. Ann Rev Genet 1998; 32: 461-93
43. Price DL, Sisodia SS. Mutant genes in familial Alzheimer's disease and transgenic models. Ann Rev Neurosci 1998; 21: 479-505
44. Gurney ME. What transgenic mice tell us about neurodegenerative disease. Bioessays 2000; 22 (3): 297-304
45. van Leuven F. Single and multiple transgenic mice as models for Alzheimer's disease. Prog Neurobiol 2000; 61 (3): 305-12
46. Janus C, Chishti MA, Westaway D. Transgenic mouse models of Alzheimer's disease. Biochim Biophys Acta 2000; 1502 (1): 63-75
47. Janus C, Phinney AL, Chishti MA, et al. New developments in animal models of Alzheimer's disease. Curr Neurol Neurosci Rep 2001; 1: 451-7
48. Chapman PF, Falinska AM, Knevett SG, et al. Genes, models and Alzheimer's disease. Trends Genet 2001; 17 (5): 254-61
49. Janus C, Westaway D. Transgenic mouse models of Alzheimer's disease. Physiol Behav 2001; 73 (5): 873-86
50. Hsiao Ashe K. Learning and memory in transgenic mice modelling Alzheimer's disease. Learn Mem 2001; 8: 301-8
51. Spooner ET, Desai RV, Mori C, et al. The generation and characterisation of potentially therapeutic Aβ antibodies in mice: differences according to strain and immunization protocol. Vaccine 2002; 21 (3-4): 290-7
52. Kawarabayashi T, Younkin LH, Saido TC, et al. Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J Neurosci 2001; 21 (2): 372-81
53. Scheuner D, Eckman C, Jensen M, et al. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med 1996; 2 (8): 864-70
54. Grubeck-Loebenstein B, Blasko I, Marx FK, et al. Immunization with beta-amyloid: could T-cell activation have a harmful effect? [letter]. Trends Neurosci 2000; 23 (3): 114
55. Dovey HF, John V, Anderson JP, et al. Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain. J Neurochem 2001; 76 (1): 173-81
56. Findeis MA. Approaches to discovery and characterization of inhibitors of amyloid beta-peptide polymerization. Biochim Biophys Acta 2000; 1502 (1): 76-84
57. Soto C, Sigurdsson EM, Morelli L, et al. Beta-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: implications for Alzheimer's therapy. Nat Med 1998; 4 (7): 822-6
58. Solomon B, Koppel R, Frankel D, et al. Disaggregation of Alzheimer beta-amyloid by site-directed mAb. Proc Natl Acad Sci U S A 1997; 94 (8): 4109-12
59. Solomon B, Koppel R, Hanan E, et al. Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer beta-amyloid peptide. Proc Natl Acad Sci U S A 1996; 93 (1): 452-5
60. Schenk D, Barbour R, Dunn W, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999; 400 (6740): 173-7
61. Games D, Adams D, Alessandrini R, et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature 1995; 373 (6514): 523-7
62. Bard F, Cannon C, Barbour R, et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 2000; 6 (8): 916-9
63. Bacskai BJ, Kajdasz ST, Christie RH, et al. Imaging of amyloid-beta deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy. Nat Med 2001; 7 (3): 369-72
64. Bacskai BJ, Kajdasz ST, McLellan ME, et al. Non-Fc-mediated mechanisms are involved in clearance of amyloid-beta in vivo by immunotherapy. J Neurosci 2002; 22 (18): 7873-8
65. Nakagawa Y, Reed L, Nakamura M, et al. Brain trauma in aged transgenic mice induces regression of established abeta deposits. Exp Neurol 2000; 163 (1): 244-52
66. DeMattos RB, Bales KR, Cummins DJ, et al. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A 2001; 98 (15): 8850-5
67. Zlokovic BV, Ghiso J, Mackic JB, et al. Blood-brain barrier transport of circulating Alzheimer's amyloid beta. Biochem Biophys Res Commun 1993; 197 (3): 1034-40
68. Chauhan NB, Siegel GJ, Lichtor T. Distribution of intraventricularly administered antiamyloid-beta peptide (Abeta) antibody in the mouse brain. J Neurosci Res 2001; 66 (2): 231-5
69. Dodart JC, Bales KR, Gannon KS, et al. Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat Neurosci 2002; 5 (5): 452-7
70. Janus C, Pearson J, McLaurin J, et al. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 2000; 408 (6815): 979-82
71. Morgan D, Diamond DM, Gottschall PE, et al. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 2000; 408 (6815): 982-5
72. Chishti MA, Yang DS, Janus C, et al. Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. J Biol Chem 2001; 276 (24): 21562-70
73. Morris RGM. Spatial localization does not require the presence of local cues. Learn Motiv 1981; 12: 239-60
74. Janus C, Zuker N, Pearson J, et al. Water maze search patterns in APP transgenic mice immunised with Aβ42 peptide [abstract]. Soc Neurosci 2001; 27: 649.5
75. Duff K, Eckman C, Zehr C, et al. Increased amyloid-β42 (43) in brains of mice expressing mutant presenilin 1. Nature 1996; 383: 710-3
76. Holcomb L, Gordon MN, McGowan E, et al. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat Med 1998; 4 (1): 97-100
77. Holcomb LA, Gordon MN, Jantzen P, et al. Behavioral changes in transgenic mice expressing both amyloid precursor protein and presenilin-1 mutations: lack of association with amyloid deposits. Behav Genet 1999; 29 (3): 177-85
78. Diamond DM, Park CR, Heman KL, et al. Exposing rats to a predator impairs spatial working memory in the radial arm water maze. Hippocampus 1999; 9 (5): 542-52
79. Morgan D, Austin L, Diamond DM, et al. Short-term Aβ vaccinations do not improve cognitive performance in aged, cognitively-impaired APP+PS1 transgenic mice [abstract]. Soc Neurosci 2001; 27: 687.11
80. Kotilinek LA, Bacskai BJ, Hyman BT, et al. Dementia associated with Aβ accumulation reversed with Aβ antibodies [abstract]. Soc Neurosci 2001; 27: 546.10
81. Kotilinek LA, Bacskai B, Westerman M, et al. Reversible memory loss in a mouse transgenic model of Alzheimer's disease. J Neurosci 2002; 22 (15): 6331-5
82. Lemere CA, Maron R, Spooner ET, et al. Nasal A beta treatment induces anti-A beta antibody production and decreases cerebral amyloid burden in PD-APP mice. Ann N Y Acad Sci 2000; 920: 328-31
83. Weiner HL, Lemere CA, Maron R, et al. Nasal administration of amyloid-beta peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease. Ann Neurol 2000; 48 (4): 567-79
84. Lemere CA, Spooner ET, Malester B, et al. Aβ immunization of PDAPP mice leads to decreased cerebral Aβ and a corresponding increase in serum Aβ [abstract]. Soc Neurosci 2002; 27: 687.10
85. Lemere CA, Spooner ET, Leverone JF, et al. Intranasal immunotherapy for the treatment of Alzheimer's disease: Escherichia coli LT and LT(R192G) as mucosal adjuvants. Neurobiol Aging 2002; 23 (6): 991-1000
86. Sigurdsson EM, Scholtzova H, Mehta PD, et al. Immunization with a nontoxic/nonfibrillar amyloid-beta homologous peptide reduces Alzheimer's disease-associated pathology in transgenic mice. Am J Pathol 2001; 159 (2): 439-47
87. Moechars D, Lorent K, Van-Leuven F. Premature death in transgenic mice that overexpress a mutant amyloid precursor protein is preceded by severe neurodegeneration and apoptosis. Neuroscience 1999; 91 (3): 819-30
88. Moechars D, Dewachter I, Lorent K, et al. Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain. J Biol Chem 1999; 274 (10): 6483-92
89. Dewachter I, van Dorpe J, Spittaels K, et al. Modeling Alzheimer's disease in transgenic mice: effect of age and of presenilin1 on amyloid biochemistry and pathology in APP/London mice. Exp Gerontol 2000; 35 (6-7): 831-41
90. Dewachter I, van Dorpe J, Smeijers L, et al. Aging increased amyloid peptide and caused amyloid plaques in brain of old APP/V7171 transgenic mice by a different mechanism than mutant presenilin1. J Neurosci 2000; 20 (17): 6452-8
91. Dewachter I, Reverse D, Caluwaerts N, et al. Neuronal deficiency of presenilin 1 inhibits amyloid plaque formation and corrects hippocampal long-term potentiation but not a cognitive defect of amyloid precursor protein [V7171] transgenic mice. J Neurosci 2002; 22 (9): 3445-53
92. Chen GQ, Chen KS, Knox J, et al. A learning deficit related to age and beta-amyloid plaques in a mouse model of Alzheimer's disease. Nature 2000; 408 (6815): 975-9
93. Cai H, Wang Y, McCarthy D, et al. BACE1 is the major beta-secretase for generation of Abeta peptides by neurons. Nat Neurosci 2001; 4 (3): 233-4
94. Luo Y, Bolon B, Kahn S, et al. Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation. Nat Neurosci 2001; 4 (3): 231-2
95. Suh SW, Jensen KB, Jensen MS, et al. Histochemically-reactive zinc in amyloid plaques, angiopathy, and degenerating neurons of Alzheimer's diseased brains. Brain Res 2000; 852 (2): 274-8
96. Chemy RA, Legg JT, McLean CA, et al. Aqueous dissolution of Alzheimer's disease Abeta amyloid deposits by biometal depletion. J Biol Chem 1999; 274 (33): 23223-8
97. Chemy RA, Atwood CS, Xilinas ME, et al. Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 2001; 30 (3): 665-76
98. Mackenzie IR, Munoz DG. Nonsteroidal anti-inflammatory drug use and Alzheimer-type pathology in aging. Neurology 1998; 50 (4): 986-90
99. Zandi PP, Anthony JC, Hayden KM, et al. Reduced incidence of AD with NSAID but not H (2) receptor antagonists: the Cache County Study. Neurology 2002; 59 (6): 880-6
100. Breitner JC. The role of anti-inflammatory drugs in the prevention and treatment of Alzheimer's disease. Annu Rev Med 1996; 47: 401-11
101. Scharf S, Mander A, Ugoni A, et al. A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease. Neurology 1999; 53 (1): 197-201
102. Lim GP, Yang F, Chu T, et al. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J Neurosci 2000; 20 (15): 5709-14
103. Lim GP, Yang F, Chu T, et al. Ibuprofen effects on Alzheimer pathology and open field activity in APPsw transgenic mice. Neurobiol Aging 2001; 22 (6): 983-91
104. Jantzen PT, Connor KE, DiCarlo G, et al. Microglial activation and beta-amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice. J Neurosci 2002; 22 (6): 2246-54
105. Simons M, Keller P, De Strooper B, et al. Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc Natl Acad Sci U S A 1998; 95 (11): 6460-4
106. Simons M, Keller P, Dichgans J, et al. Cholesterol and Alzheimer's disease: is there a link? Neurology 2001; 57 (6): 1089-93
107. Jick H, Zornberg GL, Jick SS, et al. Statins and the risk of dementia. Lancet 2000; 356 (9242): 1627-31
108. Refolo LM, Pappolla MA, LaFrancois J, et al. A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease. Neurobiol Dis 2001; 8 (5): 890-9
109. Senior K. Dosing in phase II trial of Alzheimer's vaccine suspended. Neurology 2002; 1: 3
110. Schenk D. Opinion: Amyloid-β immunotherapy for Alzheimer's disease: the end of the beginning. Nat Rev Neurosci 2002; 3 (10): 824-8
111. Seubert P. Progress on potential treatments for Alzheimer's disease based upon the amyloid hypothesis. Satellite to the 8th International Conference on Alzheimer's Disease and Related Disorders; 2002 July 20-25; Stockholm
112. Hock C, Konietzko U, Papassotiropoulos A, et al. Generation of antibodies specific for β-amyloid by vaccination of patients with Alzheimer disease. Nat Med 2002 Nov; 8 (11): 1270-5
113. Nicoll JAR, Wilkinson D, Holmes C, et al. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med 2003 Apr; 9 (4): 448-52